Bringing Retinal Health into focus
ELOVL2 Gene Therapy for Dry AMD »
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues.
Dry-AMD Overview
progressive disease
Resulting in loss of photoreceptor cells and visual acuity
Such as driving, cooking, reading, and facial recognition
There are no approved therapies
Age-Related Macular Degeneration and Geographic Atrophy»
We believe dysregulation of lipid (fatty acid) bio-synthesis resulting from declining expression of a gene known as ELOVL2 underlies Dry Macular Degeneration.
Innovation in Focus.
We are scientists, entrepreneurs and drug developers with a goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.
Visgenx in Focus.
Our goal is to develop therapeutics that slow or halt cellular senescense in macular degeneration and other age-related disorders by “turning back the clock” to a more youthful level of ELOVL2 expression.